MedTrace Logo

E-Cigarette Effects on Markers of Cardiovascular and Pulmonary Disease

NCT03863509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2023-08-21

Study results available
· View outcomes & findings →

Summary

This study is designed to enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes ("products") to well-validated cardiovascular and pulmonary disease biomarkers. Participants will be enrolled in 3 groups: exclusive e-cigarette users, exclusive cigarette smokers, and a control group of never-users. Participants can expect up to 4 weeks of study participation.

Conditions

Interventions

BEHAVIORAL

Cigarettes

smokes daily

BEHAVIORAL

E-Cigarettes

E-cigarette usage \>/= 5 days/week

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • James H Stein, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2022-03-09
Completion
2022-03-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03863509 on ClinicalTrials.gov